A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

A novel, rapid blood test demonstrated potential for detecting early-stage pancreatic cancer, according to results of a ...

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus ...